ABIGAIL SELLS: Open Payments
NPI 1326614611 · CROSSVILLE, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$373 in 18 payments from 13 companies in 2025. Trend: 2023 $440 · 2024 $531 · 2025 $373
Food & beverage: $373
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 4 | $78 |
| Amgen Inc. | 2 | $46 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $42 |
| Astellas Pharma US Inc | 1 | $33 |
| Edwards Lifesciences Corporation | 1 | $31 |
| Boston Scientific Corporation | 1 | $23 |
| GlaxoSmithKline, LLC. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Medtronic, Inc. | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
Products named: CAPLYTA, Rybelsus, Ozempic, Veozah, REPATHA, General - Pain Management, SHINGRIX, GVOKE HYPOPEN.
Industry payments across TN — which companies pay providers there.
